The Hong Kong-listed innovative drug sector, after a period of relative dormancy, has recently entered a phase of sustained upward momentum, with a clear trend of valuation recovery. On July 2nd, the Hong Kong healthcare sector experienced a broad-based surge, with VISEN PHARMA-B (02561) leading the innovative drug pack by soaring nearly 30% intraday on heavy volume. By the market close, the stock had gained 25.13% to settle at HK$25, delivering a standout performance.
This robust performance coincides with the innovative drug sector entering a new phase where earnings realization and valuation re-rating are occurring in parallel. Investors are increasingly willing to pay a premium for clear value realization. The logic of "accelerated innovation - commercial monetization - valuation uplift" is becoming a key framework for assessing the "investment certainty" of innovative drug companies. The recent share price movement of VISEN PHARMA-B serves as a typical example of the current market investment preference.
Core Product Launch Marks Commercial Inflection Point
In January this year, the company's core product, the long-acting growth hormone Lonapegsomatropin (brand name: Weizhengao®), received formal approval for marketing. It is indicated for the treatment of growth hormone deficiency in children and adolescents aged 3 years and above, marking the beginning of VISEN PHARMA-B's commercial monetization cycle.
Weizhengao® is developed based on Ascendis Pharma's TransCon prodrug technology, requiring only once-weekly subcutaneous injections. This fundamentally addresses the compliance challenges associated with traditional daily injections of short-acting growth hormones. Crucially, it is currently the only long-acting growth hormone that has demonstrated efficacy superior to daily injection formulations in two key Phase 3 clinical studies: the global heiGHt study and the China briGHt study.
Findings from these trials were published in the authoritative international journal *Hormone Research in Paediatrics*. The robust and detailed data continues to enhance clinicians' recognition of the product, solidifying its unique competitive barrier as a potential "best-in-class" therapy.
Positioning in a High-Growth Market
The domestic growth hormone market is currently undergoing a structural shift from short-acting to long-acting formulations, with substantial room for overall market expansion. According to Frost & Sullivan data, China's growth hormone market is projected to reach RMB 28.6 billion by 2030, indicating strong long-term growth momentum.
Within this growing market, Weizhengao®, as the first BIC (Best-in-Class) product in China combining the advantages of "long-acting duration" and "natural structure," is well-positioned to carve out a differentiated competitive space in the premium segment.
Rapid and Strategic Commercial Rollout
In terms of commercialization, channel deployment for Weizhengao® was largely completed prior to approval. The company is implementing a dual-track "public + non-public" strategy to ensure immediate market access post-approval.
For public hospitals, the company is collaborating with Anke Biotech, leveraging its extensive promotion experience to cover pediatric endocrinology departments. In the non-public medical sector, partnerships have been established with premium private medical institutions such as United Family Healthcare and Jiahui Health. The collaboration is deepening in the field of child growth and development, exemplified by the establishment of a "Specialized Child Growth and Development Clinic" with Shanghai United Family Hospital. This approach precisely reaches the target patient population and capitalizes on the advantages of long-term follow-up and service experience offered by these institutions.
Building Manufacturing and Supply Chain Advantages
Capacity development is progressing simultaneously. Commercialization is currently proceeding via imports, with plans for technology transfer and local production by 2028. The company is advancing local manufacturing in collaboration with its selected CDMO partner, WuXi Biologics.
This project is expected to significantly reduce production costs, enhance supply capacity, meet future volume demands, and drive several domestic upgrades, further solidifying the company's manufacturing capabilities and supply chain competitive edge.
Furthermore, VISEN announced a collaboration last month with MedTrust Health to explore novel diversified payment models. These strategic moves collectively form a complete and clear chain for commercial implementation, providing systematic support for the rapid coverage of target markets and penetration of core channels.
As product sales gradually ramp up, the company's market share is expected to increase rapidly.
Market Repricing on Commercialization Prospects
Capital re-rating often occurs when a company transcends a single cycle and demonstrates systematic value-creation capabilities. For a biotech firm transitioning from a "pipeline valuation" to a "product valuation," market focus is typically built on the positive expectation of whether its differentiated product can achieve rapid market uptake in a broad market.
Therefore, the recent strength in VISEN PHARMA-B's share price reflects the market's positive pricing of a leading player in the long-acting growth hormone space. As the commercialization and sales of Weizhengao® scale up and begin contributing to revenue, the company will steadily transition towards "product realization," and its valuation foundation is expected to gain more solid fundamental support.
Comments